89 results about "Taxane" patented technology

The application describes the first-in-human study on using a anti-KLK2xCD3 bispecific antibody and another anti-cancer drug, in particular, in particular a taxane chemotherapy or Androgen Receptor Pathway Inhibitor (ARPI), to provide enhanced antitumor efficacy with a deeper and more durable clinical response.

The present disclosure relates to a method of treating prostate specific membrane antigen (PSMA) positive progressive metastatic castration resistant prostate cancer (mCRPC) by administering a therapeutically effective amount of a PSMA binding radioligand therapy (RLT) agent, preferably [177Lu] Lu-PSMA-617 (lutetium (177Lu) vevovortitide Tailaracetam), to a taxane primarily treated patient whose disease progresses after receiving a second generation ARPI.

Disclosed are methods of treating cancer comprising administering to a subject a treatment regimen comprising a compound of Formula (I): Formula (I), or a pharmaceutically acceptable salt thereof, and a taxane anticancer agent.

The application discloses a micelle containing a taxane drug, a preparation method and application thereof. The application provides a micelle containing substance A, which comprises the following components in parts by weight: 1 part of substance A and 5-25 parts of polyethylene glycol derivatized phospholipid; the substance A is docetaxel and / or cabazitaxel; and the polyethylene glycol derivatized phospholipid comprises a polyethylene glycol part and a phospholipid part, wherein the phospholipid part is di(C 12 ‑C 24 phosphatidylethanolamine. The micelle containing the taxane drug can contain a therapeutically effective amount of the taxane drug, the drug loading capacity is as high as 6.25%-9.09%, the stability is good, and the problems in clinical application can be effectively solved.

To provide a pharmaceutical composition for treating a subject affected with cancer.SOLUTION: A pharmaceutical composition containing an effective dose of FABP5 inhibitor to be used in combination with anti-cancer therapy or additionally used to anti-cancer therapy in treatment of a subject affected with cancer, where the FABP5 inhibitor has the following structure or an enantiomer or a racemate thereof, or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None

A taxane composition and use thereof. The taxane composition is a taxane aqueous composition comprising a taxane. The taxane aqueous composition is used for treating an individual with bladder cancer by means of intravesical instillation, and has at least one of the following characteristics: (1) at least about 5% of the taxane is free taxane; and (2) the concentration of the free taxane is about 0.01 mg / ml to about 0.8 mg / ml. Alternatively, the taxane aqueous composition is used for treating a bladder cancer patient by means of intravesical instillation; after the taxane aqueous composition is administrated to the bladder cancer patient, the taxane in the plasma of the bladder cancer patient has at least one of the following characteristics: (1) the concentration of the taxane in the plasma of the bladder cancer patient is at least about 0.02 ng / ml; and (2) the AUC of the taxane in the plasma of the bladder cancer patient is at least about 0.02 h*ng / mL.

To provide, considering potential clinical oral dosing regimens for taxanes, improved tablet formulations of taxanes having higher dosage strength and higher bioavailability.SOLUTION: The invention relates to high-strength, high-bioavailability, ready-to-administer oral compositions of taxanes to be manufactured by readily scalable methods. The ready-to-administer oral composition can comprise a solid dispersion of taxanes and a hypromellose acetate succinate (HPMCAS) carrier, which is compressed into a tablet form with high taxane loading.SELECTED DRAWING: Figure 9

Provided are a product and method for preventing or treating cancer by combining an anti-EGFR antibody or a fragment (for example, an antigen-binding fragment) thereof and a taxane drug, and related applications.

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.

Provided are methods for the treatment of small cell lung cancer (SCLC) comprising administering alisertib. Also provided herein are methods for the treatment of small cell lung cancer (SCLC) comprising administering alisertib and a taxane, such as paclitaxel. Specific patient populations are contemplated in the methods and compositions disclosed herein, including patients with certain biomarkers and / or genetic profiles as well as resistant or refractory patients with certain biomarkers and / or genetic profiles.

Provided is a use of an anti-PD-1 antibody combined with a chemotherapeutic agent in the treatment of tumors such as cervical cancer or endometrial cancer. In some embodiments, the chemotherapeutic agent comprises a taxane drug and / or a platinum drug. In some embodiments, the use further comprises a use of the anti-PD-1 antibody combined with bevacizumab.

A taxane supramolecular nanocomposite. The supramolecular nanocomposite comprises a taxane active substance, including but not limited to paclitaxel, docetaxel, and cabazitaxel, as well as a self-assembling carrier, a high molecular polymer, and a dissolution promoter. The dissolution promoter may comprise one or more of alcohols, polybasic organic acids, and amino acids. Also disclosed are a preparation method and use of the supramolecular nanocomposite. The supramolecular nanocomposite is suitable for oral administration and topical application, providing effects such as increased local drug exposure concentration and efficacy, reduced systemic side effects, etc.

The present disclosure is directed to linker-payload compounds, and pharmaceutically acceptable salts, solvates, or stereoisomer thereof, comprising a structure of formula (I) which are useful as a component of antibody-drug conjugates. The disclosure also provides antibody-drug conjugates comprising the linker-payload compounds, compositions thereof, and methods of using the antibody-drug conjugates for the treatment of cancer.

The present invention provides an oral taxane pharmaceutical composition, which comprises a taxane drug and an excipient, wherein the excipient comprises a surfactant mixture, and the surfactant mixture is composed of Tween 80 and 15-hydroxystearate polyethylene glycol. The present invention significantly improves the solubility of taxane drugs (such as paclitaxel) through the synergistic solubilization effect of Tween 80 and 15-hydroxystearate polyethylene glycol, and the obtained preparation forms small particles after dilution, and can maintain the solution clear and transparent for more than 2 hours, solving the problem of rapid crystal precipitation and unfavorable absorption of the prior art preparation after dilution. The oral paclitaxel pharmaceutical composition of the present invention is combined with a P-glycoprotein inhibitor, and the oral bioavailability is significantly improved.

The invention discloses a solid tumor taxane / immunotherapy response evaluation system based on integrated machine learning and a working method thereof, and belongs to the technical field of bioinformatics and artificial intelligence crossing. The method comprises the following steps of: 1, preprocessing acquired solid tumor taxane chemotherapy / immunotherapy response transcriptome data or a source data set, and dividing a training set and a verification set; step 2, extracting overlapped genes as candidate genes from the gene expression level based on the preprocessed data; step 3, carrying out reprocessing based on the candidate genes; 4, constructing a consensus prediction model; 5, training the constructed model by adopting the training set in the step 3; and 6, verifying and screening the trained model to obtain an optimal scheme. According to the method, a stable and generalizable prediction tool for solving the problem of curative effect heterogeneity of complex combined treatment and how to accurately screen potential benefit people and avoid excessive treatment is filled.

To provide a method for treating patients having HER2-positive metastatic or locally advanced breast cancer in first-line therapy.SOLUTION: A method comprising administering a therapeutically effective amount of an anti-HER2 maytansinoid conjugate to a patient having breast cancer who has received prior treatment with a taxane.SELECTED DRAWING: None

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.

Provided is a pharmaceutically acceptable formulation comprising a taxane and an acid-activated 2-hydroxypropyl-β-cyclodextrin (CD). Also provided is a method of treating a patient with a taxane. The method comprises infusing the above formulation into the patient. Additionally provided is a method of preparing the above formulation. Further provided is an infusion bag comprising the above formulation.

The invention discloses an application of docetaxel in preparation of drugs for resisting toxoplasmosis, and belongs to the technical field of medicines. Through a series of experimental studies, it is found that docetaxel can significantly delay the onset time of mice infected with toxoplasma gondii virulent strains and effectively reduce the death rate of mice infected with toxoplasma gondii attenuated strains. Docetaxel shows a relatively strong inhibition effect in the aspect of treating related diseases caused by a virulent strain or a low virulent strain of toxoplasma gondii, and can effectively slow down the infection process and prolong the life cycle of a host. In combination with in-vitro cell experiment and in-vivo animal experiment results, the taxane drug has a good treatment prospect, can be used as a development basis of a novel toxoplasmosis-resistant drug, and promotes the realization of a novel treatment scheme.

This disclosure is directed to a method for treatment of cancer patients. The method comprises administering to the patient a pharmaceutical composition comprising nanoparticles of taxane modified with symmetrically and asymmetrically branched homopolymers. Particularly, this disclosure is directed to methods and single dose unit drug packages for treating head and neck cancer (HNC), head and neck squamous cell carcinoma (HNSCC), and other cancers with the pharmaceutical composition.

The invention provides methods and compositions for treating locally advanced or metastatic breast cancer and for enhancing immune function in an individual having locally advanced or metastatic breast cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.

Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, and intracystic injection.

Peptides that selectively bind ENAH (MENA) are described. The peptides are useful for treating certain cancers, such as triple negative breast cancer and for reducing resistance to taxane therapy.

The present disclosure provides methods for treating or preventing cancer comprising administering antigen binding molecules and taxane and / or nucleoside analogs that bind HER3. Also provided are methods for treating or preventing cancer comprising administering an antigen-binding molecule that binds HER3 and an antigen-binding molecule that binds EGFR. Also provided are pharmaceutical compositions and pharmaceutical combinations comprising such medicaments, as well as therapeutic and prophylactic methods of using the pharmaceutical compositions / pharmaceutical combinations.

The present invention concerns antibody-conjugate having general structure (2):wherein AB is an antibody capable of targeting Trop-2-expressing tumours and D is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes such as calicheamicins, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, radioisotopes, therapeutic proteins and peptides (or fragments thereof), kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogues or prodrugs thereof. These antibody-conjugates exhibit an improved therapeutic index. The invention further concerns a process for preparing the antibody-conjugate according to the invention, a method for targeting Trop-2-expressing cells, medical uses of the antibody-conjugates according to the invention.

The invention belongs to the technical field of tumor resistance, and particularly relates to a taxane composition and application thereof. The taxane composition is an aqueous taxane composition comprising taxane for use in the treatment of a subject with bladder cancer by bladder perfusion, having at least one of the following features: (1) wherein at least about 5% of the taxane is free taxane; (2) wherein the concentration of free taxane is from about 0.01 mg / ml to about 0.8 mg / ml. Or, the aqueous taxane composition is used for treating a bladder cancer patient through bladder perfusion, and after the aqueous taxane composition is applied to the bladder cancer patient, the taxane in the plasma of the bladder cancer patient has at least one of the following characteristics: (1) the concentration of the taxane in the plasma of the bladder cancer patient is at least about 0.02 ng / ml; (2) the AUC of the taxane in the plasma of the bladder cancer patient is at least about 0.02 h * ng / mL.

IT-139, sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is an intravenously administered small molecule compound. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents (e.g., platinums, vinca alkaloids, taxanes, anthracyclines). This activity is believed to arise from IT-139's novel mechanism of action that targets the GRP78 pathway. It was found that up-regulation of GRP78 is a key cancer cell survival pathway. Downregulation of GRP78 using IT-139 removes this resistance pathway allowing for chemotherapy and immuno-oncology agents to be more effective in treating cancer.

The present invention addresses the problem of providing a prophylactic and therapeutic agent for diseases caused by a type I allergic reaction accompanying administration of a platinum preparation and / or a taxane-based anticancer agent.　The present invention relates to a pharmaceutical composition for treating or preventing diseases caused by a type I allergic reaction accompanying administration of a platinum preparation and / or a taxane-based anticancer agent, the pharmaceutical composition containing a lecithinized superoxide dismutase.

The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.